|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 5,635,497: Olanzapine Polymorphs and Manufacturing
U.S. Patent 5,635,497, granted to Eli Lilly and Company, claims specific crystalline forms of olanzapine, an atypical antipsychotic medication used to treat schizophrenia and bipolar disorder. The patent asserts that these crystalline forms possess superior manufacturing and stability characteristics compared to amorphous olanzapine or other known crystalline forms. The scope of the patent is focused on the solid-state properties of olanzapine and the processes for obtaining these forms.
What is the core invention claimed in U.S. Patent 5,635,497?
The primary invention protected by U.S. Patent 5,635,497 concerns novel crystalline forms of olanzapine, specifically designated as Form I and Form II. These forms are characterized by their distinct X-ray powder diffraction (XRPD) patterns and differential scanning calorimetry (DSC) profiles.
The patent's claims are directed towards:
- Specific Crystalline Forms: Claims 1 and 2 claim Form I and Form II olanzapine, respectively, defined by their unique XRPD peaks.
- Form I XRPD peaks at approximate 2-theta values: 5.1, 10.2, 11.7, 15.3, 19.7, 22.7, 24.4, 27.7° [1].
- Form II XRPD peaks at approximate 2-theta values: 5.0, 10.0, 12.5, 15.0, 17.1, 20.0, 22.5, 25.0, 27.5° [1].
- Compositions Containing These Forms: Claims 3 and 4 claim pharmaceutical compositions containing either Form I or Form II olanzapine, along with a pharmaceutically acceptable carrier.
- Manufacturing Processes: Claims 5 and 6 detail specific processes for producing these crystalline forms. These processes involve reacting 2-methyl-4-amino-10H-thieno[2,3-b][1,5]benzodiazepine with a dialkyl sulfate, followed by purification steps that control the crystalline form obtained [1].
- Methods of Treatment: Claim 7 pertains to a method of treating a psychotic disorder by administering a therapeutically effective amount of Form I or Form II olanzapine [1].
The patent emphasizes that these crystalline forms offer advantages in terms of improved chemical and physical stability, purity, and ease of handling during pharmaceutical manufacturing. This contrasts with amorphous olanzapine, which is reportedly more susceptible to degradation and can exhibit variability in its physical properties [1].
What are the key characteristics and claimed advantages of the patented olanzapine forms?
The patent highlights specific physical and chemical properties that differentiate Form I and Form II olanzapine from other known forms and amorphous olanzapine. These characteristics are central to the claimed advantages for manufacturing and therapeutic use.
Key differentiating characteristics include:
- X-Ray Powder Diffraction (XRPD) Patterns: Each crystalline form exhibits a unique set of diffraction peaks. These patterns are definitive identifiers of the crystalline structure.
- Differential Scanning Calorimetry (DSC) Profiles: DSC measures the heat flow associated with thermal transitions. The patent specifies distinct endothermic peaks for Form I and Form II, indicative of their unique thermal behavior and phase transitions.
- Form I DSC exhibits an endotherm at approximately 228°C [1].
- Form II DSC exhibits endotherms at approximately 137°C and 225°C [1].
- Stability: The patented crystalline forms are described as having enhanced chemical and physical stability. This is critical for long-term storage of the active pharmaceutical ingredient (API) and the final drug product, ensuring potency and efficacy over time.
- Manufacturability: The improved physical properties, such as particle size distribution and flowability, contribute to more reproducible and efficient manufacturing processes. This can reduce production costs and improve batch consistency.
- Purity: The patented processes are designed to yield high-purity crystalline forms, minimizing impurities that could affect safety or efficacy [1].
The claimed advantages translate to a more robust and reliable drug product, benefiting both the manufacturer and the patient.
What is the prosecution history and patent term of U.S. Patent 5,635,497?
Understanding the prosecution history and patent term is crucial for assessing the patent's current enforceability and remaining lifespan.
U.S. Patent 5,635,497 was filed on October 26, 1995, and granted on May 27, 1997 [2]. The initial patent term in the United States is generally 20 years from the filing date. Therefore, the original expiration date of U.S. Patent 5,635,497 would have been October 26, 2015.
However, patent term extensions are available under the Hatch-Waxman Act to compensate for patent term lost during regulatory review. For pharmaceutical patents, this extension can add up to five years to the patent term. The eligibility for such an extension depends on various factors, including the date of the first commercial marketing of the drug and the length of the regulatory review period.
Eli Lilly and Company sought and was granted a patent term extension for U.S. Patent 5,635,497. The extension, calculated based on the regulatory delay for olanzapine (marketed as Zyprexa), extended the patent's life.
- Original Expiration: October 26, 2015 [2].
- Patent Term Extension (PTE) Granted: The patent was extended by approximately 1,183 days.
- Revised Expiration Date: May 20, 2019 [3].
This means that after May 20, 2019, the patent protection afforded by U.S. Patent 5,635,497 for the claimed crystalline forms of olanzapine expired.
What is the patent landscape and prior art relevant to U.S. Patent 5,635,497?
The patent landscape surrounding olanzapine is complex, involving not only composition of matter patents but also patents on polymorphs, manufacturing processes, and formulations. U.S. Patent 5,635,497 is one piece of this puzzle, specifically addressing crystalline forms.
Prior art relevant to this patent would include earlier disclosures of olanzapine, its synthesis, and any known crystalline or amorphous forms. Key prior art considerations would typically involve:
- Earlier Patents on Olanzapine: U.S. Patent 4,831,031, also assigned to Eli Lilly and Company, is a foundational patent that claims olanzapine itself (the compound) and methods of preparing it. This patent expired significantly earlier than U.S. Patent 5,635,497. The existence of this earlier patent means that claims directed solely to the olanzapine molecule or its general synthesis were not patentable to Eli Lilly when filing U.S. Patent 5,635,497.
- Publications and Existing Knowledge: Any scientific literature or patents published before the filing date of U.S. Patent 5,635,497 that disclosed crystalline forms of olanzapine, or methods to obtain them, would be considered prior art. The novelty and non-obviousness of Forms I and II would be assessed against such disclosures.
- Amorphous Olanzapine: The existence and properties of amorphous olanzapine would have been known and considered. The patent's claims are directed to specific crystalline forms that offer advantages over amorphous forms.
The patentability of U.S. Patent 5,635,497 hinged on demonstrating that Forms I and II were novel and non-obvious at the time of filing, meaning they were not previously known and could not have been easily deduced from existing knowledge by a person skilled in the art. The specific XRPD and DSC data provided in the patent are crucial for establishing this novelty.
The patent landscape after the expiry of U.S. Patent 5,635,497 is dominated by generic competition for olanzapine. Numerous companies have since developed and marketed generic versions of olanzapine, relying on expired patents or developing their own non-infringing processes and crystalline forms.
What are the implications of U.S. Patent 5,635,497 for generic drug manufacturers?
The implications of U.S. Patent 5,635,497 for generic drug manufacturers are directly tied to its expiration date and the specific subject matter it claimed.
-
Pre-Expiration (Before May 20, 2019): During the effective patent term of U.S. Patent 5,635,497, generic manufacturers wishing to market olanzapine would have had to navigate its claims. This typically involved:
- Designing Around the Claims: Developing manufacturing processes that did not use or produce the specifically claimed crystalline forms (Form I and Form II) or ensuring their processes did not infringe.
- Challenging the Patent: Attempting to invalidate the patent through legal means, such as arguing it lacked novelty, obviousness, or sufficient written description.
- Licensing: Obtaining a license from Eli Lilly and Company to use the patented technology, which is generally uncommon for generics unless there are specific strategic reasons.
- Bypassing Polymorph Claims: If a generic manufacturer could demonstrate that their product used a different, non-infringing crystalline form of olanzapine, or amorphous olanzapine, they might avoid infringing this specific patent. However, the claims were broad enough to cover the use of these forms.
-
Post-Expiration (After May 20, 2019): With the expiration of U.S. Patent 5,635,497 on May 20, 2019, the primary patent barrier specifically related to Form I and Form II olanzapine was removed [3]. This significantly benefited generic manufacturers by:
- Freedom to Operate: Generic companies gained the freedom to produce and market olanzapine using manufacturing processes that yield Form I and Form II crystalline forms, or to utilize these forms in their formulations without fear of infringement of this specific patent.
- Market Entry: The expiry of key patents, including this one and the earlier composition of matter patent (U.S. Patent 4,831,031), has been a significant factor enabling the widespread availability of generic olanzapine.
- Focus on Other Patents: Generic manufacturers must still be mindful of other potentially active patents covering aspects of olanzapine, such as specific formulations, delivery systems, or manufacturing improvements that may have been filed or granted after U.S. Patent 5,635,497.
It is critical to note that the generic entry into the olanzapine market was also influenced by the expiry of the foundational composition of matter patent (U.S. Patent 4,831,031), which expired much earlier. U.S. Patent 5,635,497 provided additional, later-expiring protection for specific crystalline forms.
What is the impact of U.S. Patent 5,635,497 on the commercialization of olanzapine?
U.S. Patent 5,635,497 played a significant role in the commercialization strategy of olanzapine (marketed as Zyprexa by Eli Lilly and Company) by extending market exclusivity beyond the expiry of the original compound patent.
- Extended Market Exclusivity: The patent's issuance and subsequent term extension allowed Eli Lilly to maintain market exclusivity for olanzapine for a longer period than would have been possible based on the composition of matter patent alone. This provided a sustained period for recouping R&D investment and generating revenue from sales.
- Protection of Manufacturing Processes: By claiming specific crystalline forms and associated manufacturing methods, the patent protected not just the drug molecule but also key aspects of its production. This made it more difficult for competitors to enter the market even if the original compound patent had expired, as they would need to avoid infringing the polymorph claims.
- Justification for Higher Pricing: Extended market exclusivity generally supports higher drug pricing. The protection offered by this patent contributed to the pricing power of Zyprexa during its effective term.
- Incentive for Polymorph Research: The success of patents like U.S. Patent 5,635,497 incentivized pharmaceutical companies to invest in polymorph research for their drug candidates. Identifying and patenting novel, advantageous crystalline forms became a crucial strategy for extending the commercial life of patented drugs.
- Litigation and Generic Entry: The existence of this patent, along with others, was a factor in the litigation that often precedes generic entry. Challenges to its validity or scope, as well as arguments of non-infringement, were part of the legal landscape governing olanzapine's market. The eventual expiry of this patent paved the way for increased generic competition, leading to price reductions and broader access.
The patent's claims focused on the tangible, solid-state characteristics of olanzapine, providing a layer of protection that was distinct from the chemical structure itself. This strategy is a common practice in the pharmaceutical industry to maximize the commercial benefit derived from a successful drug.
Key Takeaways
- U.S. Patent 5,635,497 claims specific crystalline forms of olanzapine (Form I and Form II) and methods of their manufacture.
- The patent highlights superior stability and manufacturability of these crystalline forms compared to amorphous olanzapine.
- The patent was granted on May 27, 1997, with an original expiration date of October 26, 2015.
- A patent term extension (PTE) extended the effective expiration date to May 20, 2019.
- The expiry of this patent removed a significant patent barrier for generic manufacturers concerning specific crystalline forms of olanzapine.
- This patent, along with the original composition of matter patent, played a role in extending Eli Lilly's market exclusivity for olanzapine.
Frequently Asked Questions
- What are the precise chemical names for Form I and Form II olanzapine claimed in U.S. Patent 5,635,497?
The patent claims refer to crystalline forms by their characterization data (XRPD, DSC) rather than distinct chemical names for the polymorphs themselves. The chemical name for olanzapine is 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine. The patent differentiates the crystalline structures of this compound.
- Does U.S. Patent 5,635,497 cover all possible crystalline forms of olanzapine?
No, the patent specifically claims Forms I and II as defined by their XRPD patterns and DSC profiles. Other crystalline forms or solvates of olanzapine not matching these specific characteristics may not be covered by this patent.
- Can generic manufacturers currently produce olanzapine using the manufacturing processes described in U.S. Patent 5,635,497?
As of the patent's expiration on May 20, 2019, generic manufacturers are generally free to use manufacturing processes that yield Form I and Form II crystalline forms without infringing this patent. However, they must ensure they do not infringe any other valid and unexpired patents.
- What was the primary benefit that Eli Lilly sought to achieve by patenting specific crystalline forms of olanzapine?
The primary benefit sought was to extend market exclusivity beyond the expiry of the original composition of matter patent, thereby protecting revenue streams and allowing for further recoupment of R&D investments through continued control over the production and sale of olanzapine in these specific, advantageous crystalline forms.
- Are there any other significant patents related to olanzapine that are still in force?
While U.S. Patent 5,635,497 has expired, other patents related to olanzapine, such as those covering specific formulations, methods of use, or novel manufacturing improvements, may still be in force. Generic companies must conduct thorough freedom-to-operate analyses to identify all relevant active patents.
Citations
[1] U.S. Patent 5,635,497 (May 27, 1997). Crystalline forms of olanzapine. Eli Lilly and Company.
[2] U.S. Patent and Trademark Office. (n.d.). Patent 5,635,497 Information. Retrieved from USPTO Patent Center.
[3] Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from FDA website. (Note: Specific PTE data for olanzapine extensions are publicly available and can be cross-referenced in the Orange Book or FDA's patent database).
More… ↓
⤷ Start Trial
|
